scholarly journals Repeat lung cancer screenings reveal less CXR abnormalities with different variations than first-time screening

2021 ◽  
Vol 5 (2) ◽  
Author(s):  
Tatsuo Kimura ◽  
Shinya Fukumoto ◽  
Akemi Nakano ◽  
Hideki Fujii ◽  
Yuji Nadatani ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screenings ◽  
First Time

scholarly journals Autophagy augments the self-renewal of lung cancer stem cells by the degradation of ubiquitinated p53

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Jianyu Wang ◽  
Doudou Liu ◽  
Zhiwei Sun ◽  
Ting Ye ◽  
Jingyuan Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Cell Lines ◽  
Human Cancer ◽  
Suppressor Activity ◽  
Self Renewal ◽  
Tumor Suppressor Activity ◽  
Lung Cancer Stem Cells ◽  
First Time

AbstractIt has been postulated that cancer stem cells (CSCs) are involved in all aspects of human cancer, although the mechanisms governing the regulation of CSC self-renewal in the cancer state remain poorly defined. In the literature, both the pro- and anti-oncogenic activities of autophagy have been demonstrated and are context-dependent. Mounting evidence has shown augmentation of CSC stemness by autophagy, yet mechanistic characterization and understanding are lacking. In the present study, by generating stable human lung CSC cell lines with the wild-type TP53 (A549), as well as cell lines in which TP53 was deleted (H1229), we show, for the first time, that autophagy augments the stemness of lung CSCs by degrading ubiquitinated p53. Furthermore, Zeb1 is required for TP53 regulation of CSC self-renewal. Moreover, TCGA data mining and analysis show that Atg5 and Zeb1 are poor prognostic markers of lung cancer. In summary, this study has elucidated a new CSC-based mechanism underlying the oncogenic activity of autophagy and the tumor suppressor activity of p53 in cancer, i.e., CSCs can exploit the autophagy-p53-Zeb1 axis for self-renewal, oncogenesis, and progression.

Number of procedures and time needed to diagnose lung cancer: Being right the first time

2015 ◽  
Author(s):  
Akash Verma ◽  
Jonathen Venkatachalam ◽  
Dessmon Tai ◽  
Soon Keng Goh ◽  
Ai Ching Kor ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Diagnose Lung Cancer ◽  
First Time

scholarly journals Lung cancer (C33, 34). Morbidity, mortality, accuracy of registration, localization and histological structure (population study)

2021 ◽  
Vol 67 (3) ◽  
pp. 361-367
Author(s):  
Vakhtang Merabishvili ◽  
Iuliia Iurkova ◽  
Aleksandr Shcherbakov ◽  
Evgenii Levchenko ◽  
Anton Barchuk ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Russian Federation ◽  
Federal District ◽  
Developed Countries ◽  
First Year ◽  
Histological Structure ◽  
The Real ◽  
Real Value ◽  
The Russian Federation ◽  
First Time

Lung cancer (LC) is the main cause of morbidity and mortality in the population of Russia and many economically developed countries of the world. At the same time, referring to localizations with a high mortality rate, the official data on the number of recorded primary cases (which form the incidence rate) are significantly underestimated, which is confirmed by the registration reliability index, which in many territories is higher than critical values. The aim of our study is to present the real state of the prevalence of PC in Russia, based on the newly created database (DB) of the population cancer register (PRR) of the Northwestern Federal District of the Russian Federation (NWFD RF) — the only one in Russia. We analyzed the loss of the number of primary patients who were not included in the state reporting, showed the real value of the achieved death rate of patients in the first year of dispensary observation, calculated the patterns of annual mortality of patients, the median of survival and 1 and 5-year survival of patients with lung cancer based on the database of the population cancer registry. Northwestern Federal District of the Russian Federation, on the materials of which for the first time in Russia the dynamics of changes in the detailed localization and histological structure of lung cancer was traced.

scholarly journals Serial CT changes in different components of lung cancer associated with cystic airspace in patients treated with neoadjuvant chemotherapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Peipei Dou ◽  
Yankai Meng ◽  
Hengliang Zhao ◽  
Shuai Zhang ◽  
Zhongxiao Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Correlation Coefficient ◽  
Computerized Tomography ◽  
Significant Variation ◽  
Volume Measurements ◽  
Serial Ct ◽  
First Time ◽  
Area And Volume

AbstractThe aim of this study was to observe changes in different components (solid, cystic airspace, or entire tumor) in lung cancer associated with cystic airspace following treatment with neoadjuvant chemotherapy (NC), using computerized tomography (CT). We analyzed serial (baseline, first-time follow-up, and last-time follow-up) clinical data and CT imaging in six patients treated with NC. The diameters, areas, and volumes of different tumor components (solid, cystic airspace, and entire tumor) were measured. Delta (Δ) was used to represent changes in these parameters between two examinations: Δ1(%) represents the change from baseline to first follow-up after NC, and Δ2(%) represents the change from baseline to last follow-up after NC. We used the intra-group correlation coefficient (ICC) to test for consistency between parameters as measured by two radiologists. The diameter of solid components in all lesions showed a trend of continuous reduction compared with baseline (Δ1 ranged from − 8.3 to − 46.0%, Δ2 from − 30.8 to − 69.2%). For cystic airspace and entire tumors, different lesions showed different trends over the course of treatment. For diameter, area, and volume, Δ1 of changes in the solid component ranged from − 8.3 to − 46.9%, − 19.4 to − 70.8%, and − 19.1 to − 94.7%, respectively; Δ2 ranged from − 30.8 to − 69.2%, − 50.8 to − 92.1%, and − 32.7 to − 99.8% in diameter, area, and volume, respectively. Results were inconsistent between different components of lung cancer associated with cystic airspace that was treated with NC, but the diameter, area, and volume of solid components were continuously reduced during treatment. Furthermore, area and volume measurements showed more-significant variation than diameter measurements.

scholarly journals Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancer—A Nationwide Cohort Study

Cancers ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 49
Author(s):  
Maria D’Souza ◽  
Mette Bagger ◽  
Mark Alberti ◽  
Morten Malmborg ◽  
Morten Schou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Ocular Inflammation ◽  
Patients With Cancer ◽  
Hazard Ratios ◽  
One Year ◽  
The One ◽  
First Time ◽  
Inhibitor Treatment

Purpose: To estimate the frequency of first-time ocular events in patients treated with immune checkpoint inhibitors (ICI). Methods: Patients with cancer in 2011–2018 in Denmark were included and followed. The outcomes were first-time ophthalmologist consultation and ocular inflammation. One-year absolute risks of outcomes and hazard ratios were estimated. Results: 112,289 patients with cancer were included, and 2195 were treated with ICI. One year after the first ICI treatment, 6% of the patients with cancer, 5% and 8% of the lung cancer (LC) and malignant cutaneous melanoma (MM) patients, respectively, had a first-time ophthalmologist consultation. The risk of ocular inflammation was 1% (95% confidence interval (CI) 0.4–1.2). Among patients with MM, ICI was associated with ocular inflammation in women (HR 12.6 (95% CI 5.83–27.31) and men (4.87 (95% CI 1.79–13.29)). Comparing patients with and without ICI treatment, the risk of first-time ophthalmologist consultation was increased in patients with LC (HR 1.74 (95% CI 1.29–2.34) and MM (HR 3.21 (95% CI 2.31–4.44). Conclusions: The one-year risks of first-time ophthalmologist consultation and ocular inflammation were 6% and 1%, respectively, in patients treated with ICI. In patients with LC and MM, the risk was increased in patients with ICI compared with patients without ICI.

scholarly journals Both E6 and E7 in HPV16 Promote the Glucose Uptake of GLUT1 in Lung Cancer Cells By Repressing NDRG2 Expression and Further Nuclear Translocation of β-Catenin

2021 ◽  
Author(s):  
Xin Wang ◽  
Ming-Zhe Wu ◽  
Na-Jin Gu ◽  
Shi-Yu Wang ◽  
Hong-Tao Xu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Glucose Uptake ◽  
Nuclear Translocation ◽  
Molecular Signaling ◽  
Genetic Manipulations ◽  
Ndrg2 Expression ◽  
E6 And E7 ◽  
E7 Proteins ◽  
First Time

Abstract Background: HPV16 is the most common infection subtype, among which E6 and E7 proteins are the most common carcinogenic proteins. Our previous studies found that E6 and E7 proteins regulated the expression of GLUT1 through multiple molecular signaling pathways in lung cancer. However, whether they can regulate the glucose uptake of GLUT1 and the underlying molecular mechanism has not been identified. Methods: The modulating effects of E6 or E7, NDRG2, β-catenin, and GLUT1 were detected by double directional genetic manipulations in lung cancer cell lines; The immunofluorescence was used to detect the effect of NDRG2 on the nuclear translocation of β-catenin; The glucose uptake level of GLUT1 was observed under the confocal microscope.Results: We demonstrated for the first time that E6 and E7 had inhibitory effects of NDRG2 which further resulted in increased β-catenin expression and promoted β-catenin nuclear translocation, furthermore promoted the expression and glucose uptake of GLUT1. Therefore, we hypothesized both E6 and E7 in HPV16 promoted the expression and glucose uptake of GLUT1 through HPV-NDRG2- β-catenin-GLUT1 axis. Conclusion: Our findings confirmed the regulatory role of tumor suppressor NDRG2 in the pathogenesis of lung cancer, and we further demonstrate the detail relationships among E6 and E7, NDRG2, β-catenin, and GLUT1; which provided a novel therapeutic target for tumor treatment.

scholarly journals HPV16-E6 but not E7 inhibits the antitumor activity of LKB1 in lung cancer cells by down regulating the expression of KIF7

2020 ◽  
Author(s):  
Yue Hu ◽  
Ming-Zhe Wu ◽  
Na-Jin Gu ◽  
Xue-Shan Qiu ◽  
En-Hua Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Antitumor Activity ◽  
Cancer Cells ◽  
Genetic Manipulation ◽  
Lung Cancer Cells ◽  
Hpv16 E6 ◽  
E6 And E7 ◽  
E7 Proteins ◽  
First Time ◽  
New Evidence

Abstract Background: The E6 and E7 proteins in HPV16 are the main oncogenes in the occurrence of lung cancer. In recent studies, we had found that E6 and E7 downregulated the expression of LKB1 in lung cancer cells. However, it is not clear how E6 and E7 regulate LKB1 in lung cancer cells. Methods: The double directional genetic manipulation and Nuclear plasma separation technology were performed to explore the molecular mechanism of E6 and E7 inhibiting the antitumor activity of LKB1 in well-established lung cancer cell lines. Results: E6 but not E7 significantly downregulated the expression of tumor suppressor KIF7 at protein level, and the inhibition of KIF7 further reduced the expression of LKB1 both in the nuclei and in the cytoplasm, whereas reduced the expression of p-LKB1 in the cytoplasm only. Therefore, we suggested that HPV16 E6 but not E7 downregulates the antitumor activity of LKB1 by down regulating the expression of p-LKB1 in the cytoplasm only. Conclusion: We demonstrated for the first time that E6 but not E7 inhibits the antitumor activity of LKB1 in lung cancer cells by downregulating the expression of KIF7. Our findings provided new evidence to support the important role of KIF7 in the pathogenesis of lung cancer and suggested new therapeutic targets.

scholarly journals HPV16-E6 but not E7 inhibits the antitumor activity of LKB1 in lung cancer cells by down regulating the expression of KIF7

2020 ◽  
Author(s):  
Yue Hu ◽  
Ming-Zhe Wu ◽  
Na-Jin Gu ◽  
Xue-Shan Qiu ◽  
En-Hua Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Antitumor Activity ◽  
Cancer Cells ◽  
Genetic Manipulation ◽  
Lung Cancer Cells ◽  
Hpv16 E6 ◽  
E6 And E7 ◽  
E7 Proteins ◽  
First Time ◽  
New Evidence

Abstract Background: The E6 and E7 proteins in HPV16 are the main oncogenes in the occurrence of lung cancer. In recent studies, we had found that E6 and E7 downregulated the expression of LKB1 in lung cancer cells. However, it is not clear how E6 and E7 regulate LKB1 in lung cancer cells. Methods: The double directional genetic manipulation and Nuclear plasma separation technology were performed to explore the molecular mechanism of E6 and E7 inhibiting the antitumor activity of LKB1 in well-established lung cancer cell lines. Results: E6 but not E7 significantly downregulated the expression of tumor suppressor KIF7 at protein level, and the inhibition of KIF7 further reduced the expression of LKB1 both in the nuclei and in the cytoplasm, whereas reduced the expression of p-LKB1 in the cytoplasm only. Therefore, we suggested that HPV16 E6 but not E7 downregulates the antitumor activity of LKB1 by down regulating the expression of p-LKB1 in the cytoplasm only. Conclusion: We demonstrated for the first time that E6 but not E7 inhibits the antitumor activity of LKB1 in lung cancer cells by down regulating the expression of KIF7. Our findings provided new evidence to support the important role of KIF7 in the pathogenesis of lung cancer and suggested new therapeutic targets.

Sensitive electrochemiluminescence analysis of lung cancer marker miRNA-21 based on RAFT signal amplification

2022 ◽  
Author(s):  
Qingyu Wang ◽  
Shuaibing Yu ◽  
Lianshun Zhang ◽  
Lei Wang ◽  
Jinming Kong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Functional Groups ◽  
Signal Amplification ◽  
Chain Transfer ◽  
Raft Polymerization ◽  
Polymer Chains ◽  
Cancer Marker ◽  
Reversible Addition ◽  
First Time

An electrochemiluminescence approach based on surface-initiated reversible addition-fragmentation chain transfer (SI-RAFT) was developed for miRNA-21 detection for the first time. The SI-RAFT polymerization generates polymer chains with functional groups that...

Sign in / Sign up

Export Citation Format

Share Document